{"product_id":"xr-ipsc-derived-cardiac-organoid-differentiation-kit","title":"XR iPSC-Derived Cardiac Organoid Differentiation Kit","description":"\u003c!--\nSEO TITLE:\nCardiac Organoid Differentiation Kit | Human iPSC Heart Organoids\n\nMETA DESCRIPTION:\nGenerating reproducible beating heart organoids from hPSCs can be challenging. This staged medium kit supports EB-based cardiac organoid differentiation.\n\nRECOMMENDED URL:\n\/products\/cardiac-organoid-differentiation-kit\n\nPRIMARY KEYWORDS:\nCardiac Organoid Differentiation Kit\niPSC Cardiac Organoid\nHuman Cardiac Organoid\nCardiac Organoid Culture\nCardiac Organoid Differentiation\nHeart Organoid Differentiation\n\nSECONDARY KEYWORDS:\nHuman Heart Organoid\niPSC Heart Organoid\nCardiac Organoid Medium\nBeating Cardiac Organoid\nhPSC Cardiac Differentiation\nEmbryoid Body Differentiation\nCardiac Progenitor Differentiation\nCardiomyocyte Differentiation\n3D Cardiac Model\nSpontaneously Beating Organoid\nHuman Pluripotent Stem Cell Differentiation\nChemically Defined Cardiac Differentiation\nCardiac Development Research\nCardiac Disease Modeling\nCardiotoxicity Testing\nDrug Screening\n--\u003e\n\u003cstyle\u003e\n  \/* 现代专业风全局样式 *\/\n  .pdp-container {\n    font-family: -apple-system, BlinkMacSystemFont, \"Segoe UI\", Roboto, Helvetica, Arial, sans-serif;\n    color: #333333;\n    line-height: 1.6;\n    max-width: 1200px;\n    margin: 0 auto;\n    padding: 15px;\n  }\n  \n  \/* 标题样式升级 *\/\n  .pdp-container h2 {\n    font-size: 24px;\n    color: #0B3C5D;\n    border-bottom: 2px solid #328CC1;\n    padding-bottom: 8px;\n    margin-top: 40px;\n    margin-bottom: 20px;\n    font-weight: 600;\n  }\n  \n  .pdp-container h3 {\n    font-size: 18px;\n    color: #1D2731;\n    margin-top: 30px;\n    margin-bottom: 15px;\n    font-weight: 600;\n  }\n  \n  \/* 段落与列表 *\/\n  .pdp-container p {\n    margin-bottom: 16px;\n    font-size: 15px;\n    color: #4A4A4A;\n    text-align: justify;\n  }\n  \n  .pdp-container ul,\n  .pdp-container ol {\n    padding-left: 20px;\n    margin-bottom: 24px;\n  }\n  \n  .pdp-container li {\n    margin-bottom: 10px;\n    font-size: 15px;\n    color: #4A4A4A;\n  }\n\n  .pdp-container ul li {\n    list-style-type: square;\n  }\n  \n  .pdp-container li p {\n    margin-bottom: 0;\n    display: inline;\n  }\n\n  \/* 移动端表格响应式滑动容器 *\/\n  .pdp-table-responsive {\n    width: 100%;\n    overflow-x: auto;\n    -webkit-overflow-scrolling: touch;\n    margin: 25px 0;\n    border: 1px solid #E0E0E0;\n    border-radius: 6px;\n    box-shadow: 0 2px 5px rgba(0,0,0,0.05);\n  }\n  \n  \/* 隐藏原生滚动条但保持可滑动 *\/\n  .pdp-table-responsive::-webkit-scrollbar {\n    height: 6px;\n  }\n\n  .pdp-table-responsive::-webkit-scrollbar-thumb {\n    background-color: #CBCBCB;\n    border-radius: 4px;\n  }\n\n  \/* 专业表格样式 *\/\n  .pdp-table {\n    width: 100%;\n    border-collapse: collapse;\n    min-width: 600px;\n    background-color: #FFFFFF;\n    text-align: left;\n  }\n  \n  .pdp-table th,\n  .pdp-table td {\n    padding: 12px 16px;\n    border-bottom: 1px solid #E0E0E0;\n    font-size: 14px;\n    vertical-align: top;\n  }\n\n  .pdp-table th {\n    background-color: #F1F6FA;\n    color: #0B3C5D;\n    font-weight: 600;\n  }\n  \n  .pdp-table tr:last-child td {\n    border-bottom: none;\n  }\n  \n  .pdp-table tbody tr:nth-child(even) {\n    background-color: #F8F9FA;\n  }\n  \n  .pdp-table td strong {\n    color: #0B3C5D;\n    font-weight: 600;\n  }\n\n  \/* 图片自适应安全容器 *\/\n  .pdp-img-container {\n    max-width: 600px;\n    margin: 24px auto;\n    padding: 10px;\n    border: 1px solid #EEEEEE;\n    border-radius: 8px;\n    box-shadow: 0 4px 12px rgba(0, 0, 0, 0.05);\n    background: #FFFFFF;\n    box-sizing: border-box;\n    text-align: center;\n  }\n  \n  .pdp-img-container img {\n    max-width: 100%;\n    height: auto;\n    display: block;\n    margin: 0 auto;\n    border-radius: 4px;\n  }\n\n  .pdp-img-placeholder {\n    min-height: 280px;\n    display: flex;\n    align-items: center;\n    justify-content: center;\n    padding: 30px;\n    border: 1px dashed #9EB7C8;\n    border-radius: 4px;\n    background-color: #F8FAFC;\n    color: #607D8B;\n    font-size: 14px;\n    box-sizing: border-box;\n  }\n\n  .pdp-img-caption {\n    margin: 10px 0 0;\n    font-size: 13px;\n    color: #66757F;\n    text-align: center;\n  }\n\n  \/* 流程信息块 *\/\n  .pdp-step {\n    margin-bottom: 16px;\n    padding: 16px 18px;\n    \n    background-color: #F8F9FA;\n    border-radius: 0 6px 6px 0;\n  }\n\n  .pdp-step strong {\n    color: #0B3C5D;\n  }\n\n  .pdp-step p {\n    margin: 5px 0 0;\n    text-align: left;\n  }\n\n  \/* 提示信息 *\/\n  .pdp-note {\n    margin: 24px 0;\n    padding: 16px 18px;\n    border: 1px solid #D6E6F1;\n    border-radius: 6px;\n    background-color: #F3F8FC;\n  }\n\n  .pdp-note p {\n    margin: 0;\n    color: #36576B;\n    text-align: left;\n  }\n\n  \/* 精美FAQ折叠面板样式 *\/\n  .pdp-container details {\n    background-color: #F8F9FA;\n    border: 1px solid #E0E0E0;\n    border-radius: 6px;\n    margin-bottom: 12px;\n    padding: 14px 18px;\n    transition: all 0.3s ease;\n  }\n  \n  .pdp-container details[open] {\n    background-color: #FFFFFF;\n    border-color: #328CC1;\n    box-shadow: 0 4px 10px rgba(50, 140, 193, 0.1);\n  }\n  \n  .pdp-container summary {\n    font-weight: 600;\n    color: #0B3C5D;\n    cursor: pointer;\n    font-size: 15px;\n    outline: none;\n    user-select: none;\n  }\n  \n  .pdp-container summary:hover {\n    color: #328CC1;\n  }\n  \n  .pdp-container details p {\n    margin-top: 12px;\n    margin-bottom: 0;\n    padding-top: 12px;\n    border-top: 1px dashed #E0E0E0;\n    color: #555555;\n  }\n\n  \/* 手机端间距微调 *\/\n  @media (max-width: 768px) {\n    .pdp-container h2 {\n      font-size: 20px;\n      margin-top: 30px;\n    }\n\n    .pdp-container h3 {\n      font-size: 16px;\n    }\n\n    .pdp-container p,\n    .pdp-container li {\n      font-size: 14px;\n    }\n\n    .pdp-img-placeholder {\n      min-height: 220px;\n      padding: 20px;\n    }\n  }\n\u003c\/style\u003e\n\u003cdiv class=\"pdp-container\"\u003e\n\u003ch2\u003eDescription\u003c\/h2\u003e\n\u003cp\u003eGenerating reproducible human cardiac organoids from pluripotent stem cells can be challenging. Variability in embryoid body formation, precisely timed medium changes, and inefficient progression through early cardiac lineage stages may lead to inconsistent organoid morphology or delayed functional development. Researchers therefore need a standardized cardiac organoid differentiation workflow that coordinates each induction stage while remaining practical for routine laboratory use.\u003c\/p\u003e\n\u003cp\u003eXR Cardiac Organoid Differentiation Kit is a chemically defined, staged culture system designed to direct human pluripotent stem cells, including induced pluripotent stem cells, toward multi-lineage cardiac organoids. The protocol begins with single-cell aggregation in a low-attachment U-bottom plate and proceeds through sequential treatment with Cardiac Organoid Differentiation Media A, B, C, and D.\u003c\/p\u003e\n\u003cp\u003eEach medium is assigned to a defined phase of the differentiation workflow, supporting progression from embryoid body formation through mesendoderm induction, cardiac lineage specification, and cardiac organoid maintenance. Under the documented culture conditions, rhythmic spontaneous beating may be observed by approximately Day 8–10, providing a visible functional readout of cardiac differentiation.\u003c\/p\u003e\n\u003cp\u003eThis cardiac organoid differentiation kit supports the generation of up to 48 organoids and provides a structured platform for researchers studying human heart development, cardiomyocyte differentiation, three-dimensional cardiac models, and related cardiac research applications.\u003c\/p\u003e\n\u003ch2\u003eSpecifications\u003c\/h2\u003e\n\u003cdiv class=\"pdp-table-responsive\"\u003e\n\u003ctable class=\"pdp-table\"\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct Name\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eXR Cardiac Organoid Differentiation Kit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHuman pluripotent stem cell cardiac organoid differentiation medium kit\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eStarting Cell Type\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHuman pluripotent stem cells, including human iPSCs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eCulture Format\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEmbryoid body-based three-dimensional differentiation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRecommended Plate Format\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e96-well low-attachment U-bottom plate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eDifferentiation System\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSequential four-medium induction workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMedium A\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e10 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMedium B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e40 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMedium C\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e20 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eMedium D\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e60 mL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRecommended Volume\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e200 μL per well during the documented differentiation workflow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eKit Capacity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports differentiation of up to 48 cardiac organoids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFunctional Observation\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRhythmic spontaneous beating may be observed at approximately Day 8–10 under the documented conditions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eGrade\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFor Research Use Only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2\u003eKit Components\u003c\/h2\u003e\n\u003cdiv class=\"pdp-table-responsive\"\u003e\n\u003ctable class=\"pdp-table\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eComponent\u003c\/th\u003e\n\u003cth\u003eVolume\u003c\/th\u003e\n\u003cth\u003eWorkflow Stage\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac Organoid Differentiation Medium A\u003c\/td\u003e\n\u003ctd\u003e10 mL\u003c\/td\u003e\n\u003ctd\u003eInitial cardiac differentiation induction after embryoid body formation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac Organoid Differentiation Medium B\u003c\/td\u003e\n\u003ctd\u003e40 mL\u003c\/td\u003e\n\u003ctd\u003eContinued lineage induction during the early differentiation phase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac Organoid Differentiation Medium C\u003c\/td\u003e\n\u003ctd\u003e20 mL\u003c\/td\u003e\n\u003ctd\u003eSubsequent cardiac organoid differentiation stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiac Organoid Differentiation Medium D\u003c\/td\u003e\n\u003ctd\u003e60 mL\u003c\/td\u003e\n\u003ctd\u003eCardiac organoid maintenance and maturation phase\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2\u003eFeatures\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eStaged cardiac organoid differentiation system for human pluripotent stem cells and human iPSCs\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eChemically defined workflow designed to reduce dependence on undefined induction components\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eFour sequential cardiac organoid media corresponding to distinct differentiation stages\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEmbryoid body-based protocol compatible with 96-well low-attachment U-bottom plates\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSupports generation of multi-lineage three-dimensional cardiac organoids\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eDocumented workflow supports up to 48 cardiac organoids per kit\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eRhythmic spontaneous beating may become visible at approximately Day 8–10\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eSuitable for standardized human cardiac organoid culture and differentiation studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCardiac Organoid Differentiation Workflow\u003c\/h2\u003e\n\u003cp\u003eThe protocol uses a timed, sequential medium-change strategy. The starting iPSC culture should be in good condition and reach approximately 80% confluence before differentiation begins. Individual cell lines may require routine upstream optimization to achieve consistent aggregation and differentiation performance.\u003c\/p\u003e\n\u003cdiv class=\"pdp-step\"\u003e\n\u003cstrong\u003ePreparation: iPSC Culture\u003c\/strong\u003e\n\u003cp\u003eBegin the differentiation experiment when the iPSC culture reaches approximately 80% confluence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pdp-step\"\u003e\n\u003cstrong\u003eEB Formation: 24 Hours Before Day 0\u003c\/strong\u003e\n\u003cp\u003eDissociate iPSCs into single cells and culture them in a 96-well low-attachment U-bottom plate for 24 hours to generate embryoid bodies.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pdp-step\"\u003e\n\u003cstrong\u003eDay 0: Differentiation Medium A\u003c\/strong\u003e\n\u003cp\u003eAfter embryoid body formation, define this point as Day 0. Replace the culture medium with Cardiac Organoid Differentiation Medium A at 200 μL per well and culture for 36–40 hours.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pdp-step\"\u003e\n\u003cstrong\u003eDay 1.5: Differentiation Medium B\u003c\/strong\u003e\n\u003cp\u003eReplace Medium A with Cardiac Organoid Differentiation Medium B. Continue culture for three consecutive days, replacing the medium daily.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pdp-step\"\u003e\n\u003cstrong\u003eDay 5.5: Differentiation Medium C\u003c\/strong\u003e\n\u003cp\u003eReplace Medium B with Cardiac Organoid Differentiation Medium C. Perform an additional Medium C change on Day 6.5.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pdp-step\"\u003e\n\u003cstrong\u003eDay 7.5 and Later: Differentiation Medium D\u003c\/strong\u003e\n\u003cp\u003eReplace Medium C with Cardiac Organoid Differentiation Medium D. Continue changing Medium D every other day until the cardiac organoids reach the desired stage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pdp-note\"\u003e\n\u003cp\u003e\u003cstrong\u003eFunctional observation:\u003c\/strong\u003e Under the documented conditions, cardiac organoids may show rhythmic spontaneous beating when examined by microscopy at approximately Day 8–10.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pdp-img-container\" style=\"text-align: center;\"\u003e\n\u003cimg alt=\"Human iPSC cardiac organoid differentiation timeline showing embryoid body formation and staged cardiac induction\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0521\/5312\/2997\/files\/3_1_f23f3a5f-a621-4a42-b339-565a2effb0cd.jpg?v=1784006176\" style=\"float: none;\"\u003e\n\u003cp class=\"pdp-img-caption\"\u003eHuman iPSC cardiac organoid differentiation timeline showing embryoid body formation and staged cardiac induction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch2\u003ePerformance Data\u003c\/h2\u003e\n\u003ch3\u003eOrganoid Formation During Staged Differentiation\u003c\/h3\u003e\n\u003cp\u003eThe documented morphology images show the progression from an iPSC culture to a compact embryoid body and a gradually enlarging three-dimensional organoid during the staged differentiation process. Images collected at Day 0, Day 1.5, Day 5.5, and Day 7.5 illustrate changes in aggregate size and organization as the culture advances through the cardiac induction workflow.\u003c\/p\u003e\n\u003cp\u003eConsistent initial aggregate formation is an important starting point because differences in embryoid body size, shape, or cell number can influence downstream cardiac organoid differentiation. Researchers should use healthy pluripotent stem cell cultures and maintain consistent dissociation, seeding, and medium-change practices.\u003c\/p\u003e\n\u003ch3\u003eCardiac Marker Expression\u003c\/h3\u003e\n\u003cp\u003eImmunofluorescence images supplied with the product documentation show cardiac-associated staining for α-actinin and cardiac troponin T. α-Actinin is commonly used to visualize sarcomeric organization in differentiated cardiomyocytes, while cardiac troponin T is a widely used cardiac lineage marker.\u003c\/p\u003e\n\u003cdiv class=\"pdp-img-container\" style=\"text-align: center;\"\u003e\n\u003cimg alt=\"Alpha-actinin and cardiac troponin T immunofluorescence staining in human iPSC-derived cardiac organoids\" src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0521\/5312\/2997\/files\/1_cc00eacc-38ae-4c6b-a932-9a4a2406e1a3.jpg?v=1784006176\" style=\"float: none;\"\u003e\n\u003cp class=\"pdp-img-caption\"\u003eAlpha-actinin and cardiac troponin T immunofluorescence staining in human iPSC-derived cardiac organoids.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003ch2\u003eApplications\u003c\/h2\u003e\n\u003cp\u003eXR Cardiac Organoid Differentiation Kit provides a three-dimensional human cardiac differentiation platform for laboratories that need greater structural and biological complexity than conventional two-dimensional cardiomyocyte cultures. The staged system can be incorporated into cardiac research workflows that require EB-based organoid formation, cardiac lineage induction, and observation of spontaneous contractile activity.\u003c\/p\u003e\n\u003ch3\u003eHuman Cardiac Development Research\u003c\/h3\u003e\n\u003cp\u003eHuman cardiac organoids can provide an in vitro system for examining cellular organization and phenotypic changes during early cardiac differentiation. The timed transition from embryoid body formation to cardiac lineage induction makes the kit suitable for research focused on human heart development and developmental biology.\u003c\/p\u003e\n\u003ch3\u003eiPSC Cardiac Differentiation Studies\u003c\/h3\u003e\n\u003cp\u003eThe kit supports directed differentiation of human iPSCs through multiple cardiac induction stages. It may be used to investigate how cell-line characteristics, starting culture quality, or experimental treatments influence cardiomyocyte differentiation and cardiac organoid development.\u003c\/p\u003e\n\u003ch3\u003eThree-Dimensional Cardiac Models\u003c\/h3\u003e\n\u003cp\u003eUnlike a conventional two-dimensional cardiomyocyte monolayer, an iPSC cardiac organoid provides a three-dimensional aggregate format. This format can support research involving tissue-level organization, cell-to-cell interactions, cardiac marker expression, and spontaneous beating behavior.\u003c\/p\u003e\n\u003ch3\u003eCardiac Disease Modeling\u003c\/h3\u003e\n\u003cp\u003eWhen combined with appropriately characterized patient-derived or genetically modified iPSC lines, cardiac organoid culture may support research into disease-associated cardiac phenotypes. Experimental suitability should be validated for each cell line and disease model.\u003c\/p\u003e\n\u003ch3\u003eDrug Screening and Cardiotoxicity Research\u003c\/h3\u003e\n\u003cp\u003eBeating cardiac organoids may be incorporated into exploratory drug-screening or cardiotoxicity-testing workflows that assess morphology, viability, cardiac marker expression, or changes in contractile behavior. The kit itself does not include analytical assays, imaging systems, or compound-response validation tools.\u003c\/p\u003e\n\u003ch3\u003eCardiac Regenerative Medicine Research\u003c\/h3\u003e\n\u003cp\u003eThe system may support basic research into cardiac lineage specification, cardiomyocyte development, tissue organization, and other questions relevant to cardiac regenerative biology. The product is intended exclusively for research use and is not intended for clinical or therapeutic applications.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eHuman iPSC cardiac organoid differentiation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHuman heart organoid culture\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eEmbryoid body-based cardiac differentiation\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiomyocyte differentiation research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiac progenitor and cardiac lineage studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eHuman heart development research\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eThree-dimensional cardiac model development\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiac disease modeling using selected iPSC lines\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eExploratory drug screening and cardiotoxicity studies\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eCardiac marker expression and organoid morphology analysis\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eWhy Choose a Staged Cardiac Organoid Differentiation System?\u003c\/h2\u003e\n\u003cp\u003eCardiac organoid differentiation is highly dependent on timing. Applying the same culture conditions throughout the entire process may not provide the changing signals required as pluripotent cells progress through early lineage specification and cardiac organoid development.\u003c\/p\u003e\n\u003cp\u003eXR Cardiac Organoid Differentiation Kit separates the workflow into four sequential medium stages. This format provides researchers with a defined schedule for initiating differentiation, continuing early cardiac induction, supporting subsequent organoid development, and maintaining the resulting cardiac organoids.\u003c\/p\u003e\n\u003cp\u003eThe 96-well embryoid body format also supports parallel processing of multiple organoids. By standardizing the plate format, medium volume, and timing of medium changes, laboratories can establish a more structured cardiac organoid culture workflow while retaining the ability to optimize cell-line-specific parameters.\u003c\/p\u003e\n\u003ch2\u003eImportant Considerations\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp\u003eUse healthy, undifferentiated human pluripotent stem cell cultures before beginning the protocol.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eBegin differentiation at approximately 80% iPSC confluence, as stated in the documented workflow.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eGenerate uniform embryoid bodies by maintaining consistent single-cell preparation and seeding conditions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eFollow the specified medium sequence and timing because each medium corresponds to a different differentiation stage.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eUse 200 μL per well during the documented 96-well differentiation workflow.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eMonitor aggregate morphology and spontaneous beating by microscopy during cardiac organoid development.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp\u003eOptimize starting cell number, dissociation conditions, and upstream iPSC culture practices for each cell line when necessary.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFAQ\u003c\/h2\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is the XR Cardiac Organoid Differentiation Kit used for?\u003c\/summary\u003e\n\u003cp\u003eXR Cardiac Organoid Differentiation Kit is used to direct human pluripotent stem cells, including human iPSCs, through an embryoid body-based workflow toward three-dimensional cardiac organoids. The kit contains four sequential differentiation media for cardiac induction and organoid maintenance.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is the difference between a cardiac organoid and a two-dimensional cardiomyocyte culture?\u003c\/summary\u003e\n\u003cp\u003eA cardiac organoid is a three-dimensional cellular aggregate that can provide greater structural organization and cell-to-cell interaction than a conventional two-dimensional cardiomyocyte monolayer. This kit is specifically designed for EB-based cardiac organoid differentiation rather than only flat cardiomyocyte culture.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eCan this kit be used for human iPSC cardiac organoid differentiation?\u003c\/summary\u003e\n\u003cp\u003eYes. The documented protocol begins with human iPSCs and directs them through embryoid body formation followed by sequential cardiac differentiation using Media A, B, C, and D.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eHow are embryoid bodies generated for cardiac organoid culture?\u003c\/summary\u003e\n\u003cp\u003eHuman iPSCs are dissociated into single cells and cultured for 24 hours in a 96-well low-attachment U-bottom plate. The resulting embryoid bodies are designated as Day 0 before Cardiac Organoid Differentiation Medium A is added.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eHow many cardiac organoids can be generated with one kit?\u003c\/summary\u003e\n\u003cp\u003eThe supplied medium volumes support differentiation of up to 48 cardiac organoids when the documented 96-well workflow and recommended medium volumes are followed.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhen do iPSC-derived cardiac organoids begin to beat?\u003c\/summary\u003e\n\u003cp\u003eUnder the documented culture conditions, rhythmic spontaneous beating may be observed by microscopy at approximately Day 8–10. The exact timing may vary with the iPSC line, starting culture quality, aggregate uniformity, and laboratory conditions.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat is the cardiac organoid differentiation timeline?\u003c\/summary\u003e\n\u003cp\u003eEmbryoid bodies are prepared for 24 hours before Day 0. Medium A is used from Day 0 for 36–40 hours, Medium B begins at Day 1.5 with daily changes for three days, Medium C begins at Day 5.5 and is replaced again on Day 6.5, and Medium D begins at Day 7.5 with every-other-day medium changes.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eWhat cardiac markers are shown in the product data?\u003c\/summary\u003e\n\u003cp\u003eThe product documentation includes immunofluorescence images for α-actinin and cardiac troponin T. These markers are commonly used in cardiac differentiation research to assess cardiomyocyte-associated structural and lineage characteristics.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eIs this a chemically defined cardiac differentiation system?\u003c\/summary\u003e\n\u003cp\u003eYes. The product is described as a chemically defined cardiac organoid-directed differentiation system consisting of four staged culture media.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eCan this cardiac organoid kit be used for disease modeling?\u003c\/summary\u003e\n\u003cp\u003eThe resulting iPSC cardiac organoids may be incorporated into research workflows involving cardiac disease modeling when suitable patient-derived, control, or genetically modified iPSC lines are used. Researchers should validate the organoid phenotype and experimental endpoints for each model.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eCan beating cardiac organoids be used for drug screening or cardiotoxicity testing?\u003c\/summary\u003e\n\u003cp\u003eCardiac organoids may be incorporated into exploratory drug-screening and cardiotoxicity research workflows that measure viability, morphology, cardiac marker expression, or contractile behavior. Additional validated assays and analytical equipment are required because they are not included with the differentiation kit.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eDoes the kit include a low-attachment plate or cell dissociation reagent?\u003c\/summary\u003e\n\u003cp\u003eThe documented kit contents list Cardiac Organoid Differentiation Media A, B, C, and D. A 96-well low-attachment U-bottom plate, cell dissociation reagent, iPSC culture reagents, extracellular matrices, and analytical assays are not listed as kit components.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cdetails\u003e\n\u003csummary\u003eIs XR Cardiac Organoid Differentiation Kit intended for clinical use?\u003c\/summary\u003e\n\u003cp\u003eNo. This cardiac organoid differentiation kit is intended for research use only and is not intended for diagnostic, therapeutic, transplantation, or clinical applications.\u003c\/p\u003e\n\u003c\/details\u003e\n\u003cp\u003e\u003cem\u003eFor Research Use Only. Not intended for diagnostic, therapeutic, or clinical use.\u003c\/em\u003e\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c!-- Product Schema --\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003c!-- FAQPage Schema --\u003e\n\u003cp\u003e \u003c\/p\u003e","brand":"XRbio","offers":[{"title":"1Kit","offer_id":52798266409141,"sku":"XR-iCardOrg-Kit","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0521\/5312\/2997\/files\/2_7a7e46fa-9339-4af2-a9fc-81f7bcac225a.jpg?v=1784005738","url":"https:\/\/biofargo.com\/products\/xr-ipsc-derived-cardiac-organoid-differentiation-kit","provider":"Biofargo","version":"1.0","type":"link"}